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Summary. To reduce the opportunities for human immunodeficiency virus type 
1 (HIV-1) to evade vaccine induced immunity, the development of subunit 
vaccines must focus on the characterization f immunogenic epitopes, which 
are major targets for the immune system. The most dominant site for elicitation 
of neutralising immune response islocated on the external envelope glycoprotein 
gp 120 within the third variable domain (V3). To overcome virus type specificity 
of antibodies directed to the V3-domain we designed a 36 amino acids long 
gp 120/V3-consensus peptide (V3-C36) based on published biological data and 
sequence comparisons of various HIV-t virus isolates. This peptide contains a
conserved core s quence which is suggested to form a surface-exposed [3-turn. 
This peptide also includes T-cell epitopes defined in mice and humans, an 
ADCC-epitope and two highly conserved cysteine residues which were oxidized 
to form a cystine derivate, hus allowing correct peptide folding. In ELISA- 
tests, this peptide reacts with at least 90% of randomly selected sera of European 
and African patients infected with HIV-1 and is recognized by three different 
HIV-1/V3 "type-specific" antisera (MN, RF, IIIB-strain). Using this peptide 
as immunogen i  rabbits, antisera could be raised with highly cross-reactive 
and HIV-1/IIIB strain neutralizing properties. Moreover, HTLV/HIV-1/IIIB 
specific ytotoxic T-lymphocytes (CTLs) of BALB/c mice infected with a gp t 20 
recombinant vaccinia virus recognized the central 16- and 12-mer peptides of 
the V3-C36 consensus peptide in cytolytic assays, indicating perfect compatibility 
of the consensus peptide with the IIIB-primed CTLs. The DNA-sequence n- 
coding the V3-consensus loop region might be an important component in 
newly designed recombinant subunit vaccines. In addition, due to its broad 
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serological reactivity, the V3-consensus peptide might play an important role 
in special diagnostic purposes. 
Introduction 
Several domains of the HIV- 1 glycoprotein complex have been shown to induce 
virus neutralizing antibodies in experimental nimals when applicated in the 
appropriate form. Amongst those, the most dominant neutralization site is 
located within the third variable domain (V3) of the HIV-1 outer envelope 
protein gp 120. The V3-1oop of the gp 120 was described as the only hyper- 
variable surface exposed antigenic region without consensus equence for N- 
glycosylation and was early discussed in its immunological importance [20]. 
Deletion of the flanking cysteine residues 296 and 331 results in non infectious 
mutants. Actually, this region was verified by several aboratories to be the 
dominant neutralizing epitope on the external glycoprotein of HIV [8, 11, 21, 
24, 25]. Small peptides are sufficient o induce neutralizing antibodies [7, 13, 
14, 23]. This sequence contains a potential, in various virus isolates highly 
conserved [3-turn motif (GPGR) [ 19, 15]. Flanking residues eem to be critical 
for antibody binding, virus type specific neutralization, inhibition of syncytia 
formation and stabilization of the structure of the V3-1oop. Recent publications 
indicate that disease progression in AIDS patients and vaccine induced im- 
munity in experimental nimals might be directly correlated with V3-specific 
antibody titers [1, 6]. This hypothesis is supported by the observation that 
virus is transmitted from HIV positive mothers to their children during preg- 
nancy in the absence of high-affinity maternal antibodies to gp 120/V3. In 
contrast, mothers with high titers of V3-specific antibodies could be shown only 
in few cases to transmit heir HIV to their children during pregnancy [6]. 
How anti-V3-neutralizing antibodies actually inhibit infection and syncytia 
formation is not clear to date. One possibility is sterical hindrance by bound 
antibodies inhibiting direct interaction of the gp 120/C4 region with the CD4 
receptor molecule. Recent results [3, 12] suggest he involvement of cellular, 
cell surface exposed proteases as potential secondary dsorption site for gp 120/ 
V3 and propose cleavage of gp 120 in the GPGR motif of the V3-1oop. This 
process possibly induces structural rearrangements thus stabilizing the inter- 
action of the gp 120/C4 region with the CD4 receptor [12, 16] or enabling p 41 
mediated membrane fusion events [3]. 
The characterization of the V3-1oop as an ADCC-target region (aa 315- 
329) is of special interest with respect o the induction of immune response 
capable to eliminate HIV-infected cells [ 17, 18]. Further, a HIV- 1/IIIB derived 
minimal peptide of gp 120/V3 was shown to be recognized as target for cellular 
immune response in BALB/c mice immunized with IIIB-env recombinant vac- 
cinia virus [27-29]. CTLs raised against he IIIB- and against he MN-specific 
sequences by an env-recombinant vaccinia virus were completely not cross- 
reactive. Reciprocal exchange of a single amino acid between the two peptides 
led to a complete reversal recognition by primed CTLs. In addition, CTL 
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responses to this determinant were detected iwth the H2-D d haplotype only. 
V3-IIIB derived synthetic peptides were shown to stimulate T-helper cell func- 
tion by PBL from HIV infected, asymptomatic patients [5]. Recently also CTL 
activity could be demonstrated and characterized in a similar patient population 
[43. 
Sequence analysis of HIV-1 virus isolates in Europe and U.S.A. demon- 
strated that V3 heterogeneity is limited [15, 26]. The majority of the sequenced 
virus isolates could be classified as variants similar to MN- or SC-like strains. 
Sequence alignment revealed five arbitrary virus families: the first one consisting 
of MN, SF, SC, second of CDC4 and NY5, third of RF, fourth of ELI, Z6 
and MAL and the last of Z3 [22]. Based on serum cross reactivities Goudsmit 
et al. [9] discriminated three virus families including following prototype mem- 
bers: SF and RF; ELI, Z6 and MAL; Z3, CDC4 and NY5. 
The knowledge about V3-heterogeneity and its involvement in ADCC- and 
CTL-reaction in virus neutralization in combination with geographic distri- 
bution of individual V3-family clusters timulated us to design a V3-consensus 
domain. This approach aims to investigate whether the antigenicity and im- 
munogenicity of the epitope may be extended by using a rationally designed 
variant of the HIV-1 dominant neutralizing epitope V3 (V3-C36). The corre- 
sponding DNA sequence could be included as an important component in 
future subunit vaccines. Another approach aims to develop a group specific 
diagnostic, possibly prognostic antigen for detection of V3 specific antibodies 
in patients. 
Materials and methods 
Sequence comparison 
The design of the V3 consensus sequence was based on the comparison of a considerable 
number of different, independent HIV-1 isolates from Europe, U.S.A. and Africa. Optimal 
sequence alignments of the various V3 domains were achieved according to, chemical and 
functional similarities of the individual residues. The number of theoretically necessary 
mutation events in DNA sequence was not included. The constructed sequence includes 
the neutralization-active highly conserved GPGR motif, which is predicted to f rm a [3- 
turn (unpubl. data), the H2-D d restricted mouse CTL epitope, the ADCC-target domain 
and the flanking cysteine residues thus allowing the formation of a disulfide bridge and 
stabilization of the peptide structure. The sequence of this V3-peptide 36 amino acids in 
length (V3-C36) is shown in Fig. 1 B. 
Peptide synthesis 
Peptide synthesis was done in a 9050 peptide synthesizer (Milligen) using Fmoc (9-flu- 
orenylmethyloxycarbonyl)-protected amino acids. The first residue was coupled to the resin 
by an acid-stable amide anchor group (Tentagel AM; purchased from Rapp polymere, 
Tfibingen, Federal Republic of Germany). t-Butyl (Ser, Thr, Tyr, Cys, Asp,, Glu, His), t- 
butoxycarbonyl (Lys), and 4-methoxy-2,3,6-trimethylbencenesulfonyl (Arg) groups were 
used for side chain protection. Fmoc protected amino acids were converted to hydroxy- 
benzotriazol-activated esters by treatment with 0.75 mmol of hydroxybenzotriazol and 
0.6mmol diisopropylcarbodiimide p r mmol of amino acid for 10rain in 
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Fig. 1. A Sequence comparison of the gpl20 major neutralizing epitope V3 of various 
European, American and African HIV-1 virus strains. Shaded sections within the group 
of the depicted isolates are highly conserved (> 50%). B V3-consensus peptides: 36-mer 
(V3-C36), 16-mer (V3-C16), 12-mer (V3-C12), and 10-mer (V3-C10) 
N,N'dimethylformamide. The subsequent coupling reaction was performed in 
dimethylformamide. After the coupling reactions, Fmoc-groups were removed with 20% 
piperidine in dimethylformamide followed by a series of washed with dimethylformamide 
(all solvents were purchased from Merck AG, Darmstadt, Federal Republic of Germany; 
Fmoc-protected amino acids were from Bachem AG, Bubendorf, Switzerland; all chemicals 
from Aldrich, Steinheim, Federal Republic of Germany). After synthesis, side chain pro- 
tecting groups were removed by a 12h treatment in trifluoracetic acid containing 5% 
mercaptoethanol, 3% thioanisol, 3% phenol at room temperature. The peptide was pre- 
cipitated in an excess of ice-cold t-butyl-ethyl ether, washed several times, suspended in
high volume of 1.5% ammoniumcarbonate in order to allow the preferential formation of 
intramolecular cysteine derivates and stirred over night. The peptide was lyophilized and 
purified by reversed phase high performance liquid chromatography (HPLC) using a gra- 
dient of 0-70% acetonitrile in 0.1% trifluoracetic acid. The sequences of the peptides were 
checked by amino acid analysis and the peptides were stored as lyophilized material at 
4 °C. In addition to V3-C36 several subfragments were synthesized. 
EL ISA  test 
500 ng of purified V3-C36 peptide per well were coupled over night in 0.2 M sodium carbonate 
buffer, pH 9.5 to 96 well microtiter plates (Dynotech). Coupling of shorter peptides rep- 
resenting central sequences of various V3 domains were adjusted to the molar ratio of the 
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described 36 amino acid V3-consensus peptide. Free protein binding sites were saturated 
by a 2 h incubation with gelatin solution (5 mg/ml; Sigma Chemicals, Munich, Federal 
Republic of Germany). Before and after addition of the respective serum dilutions in PBS 
(2 h, 37 °C) the plates were washed several times with PBS containing 0.5% Tween 20. The 
peroxidase labeled second antibody (rabbit anti humans, swine anti rabbit IgG, rabbit anti 
mouse IgG or rabbit anti goat IgG; Dako, Hamburg, Federal Republic of Germany) was 
added in a dilution of 1/1000 in PBS/0.5% Tween 20. Staining was done in 0.1 M phosphate 
buffer, pH6.0 containing 0.5mg/ml o-phenytenediamin a d 0.1% H20 2 for 10rain, the 
reaction was stopped with 1 M H2804, and optical density was determined at 486 nm. 
Production of anti peptide sera 
For the production of anti peptide specific antibodies in rabbits, 200 gg of the dissolved 
V3-C36 were used in an emulsion with complete Freund's adjuvant (CFA). Booster injections 
were performed four times with 200 gg of the V3-C36 in an emulsion of incomplete Freund's 
adjuvant in four week intervals (serum A). 
In a second approach, V3-C36 was coupled to ovalbumin via carboxyterminal COOH- 
group of the peptide using water soluble 1-ethyl-3,3-dimethyl-aminopropyl-carbodiimide 
(EDC; Sigma Chemical Company, St. Louis, MO, U.S.A.). For the first immunisation 
500 gg of the coupled peptide (OvaV3-C36) were emulgated in complete Freund's adjuvant. 
Booster-injecrions were performed in 4 week intervals with 500 gg of the coupled peptide 
in incomplete Freund's Adjuvant (serum B). The V3-C36 anti peptide sera were analysed 
by ELISA using various V3-derived peptides and by conventional Western blot analysis 
using p55/V3 fusion proteins as antigen [31]. 
HIV neutralisation assay 
100 tissue culture infectious doses (TCIDs0) of HIV-1/HTLV-IIIB were incubated for 1 h 
at 37 °C with different dilutions of heat inactivated rabbit antisera. About 106/ml Jurkat 
CD4 + cells uspended in RPMI 1640 culture medium with 10% inactivated fetal calf serum 
and 2 gg/ml polybrene were infected with the preincubated mixtures and seeded into 4 
individual microtiter wells (100 gl/well). After three days 50% of culture medium was 
exchanged by fresh medium without polybrene; 20% fresh medium was added in 3-4 days 
intervals. After 2 and 3 weeks, 50% of the medium was replaced. The removed medium 
was concentrated with PEG (polyethylenglycol) and tested for reverse transcriptase activity 
with poly rA : dT and Mg + + as described previously [10]. Cell fusion was evaluated by 
microscope controls. Cultures with either reverse transcriptase activity or giant cell for- 
marion were considered as positive, cultures without parameters were regarded negative. 
Mouse cytotoxic T-cell recognition 
Spleen cells from BALB/c mice, harvested 2 months after immunization with an gp 120- 
IIIB recombinant vaccinia virus VSC25 (1 x 88 PFU/mouse) were used as effector cells. 
The isolated cells were restimulated for 7 days with the gp 120-IIIB recombinant vaccinia 
virus (2 x 107 PFU/cell). Target cells (p 815 mastozytoma cells) were incubated for 1 h with 
different concentrations of the peptides (10 gM, 0.1 gM, 1 nM) and tested in a 3 h cytolytic 
assay for SlCr-release using different arget/effector-cell ratios [27]. 
Results 
Reactivity of  the V3-C36 peptide with AIDS patient sera 
As a consequence of  the isolate-specificity of neutralizing antibodies directed 
against the V3-1oop, we designed a 36 amino acid consensus peptide (V3-C36) 
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including the highly conserved GPGR-motif, a mouse-specific T-cell epitope 
and the highly conserved flanking cysteine residues essential for the stabilisation 
of the secondary and tertiary structure of the peptide. The design was based 
on published biological data and sequence comparisons ofa number of different 
and independent HIV-1 isolates derived from Europe, U.S.A. and Africa 
(Fig. 1). 
The cysteine residues were oxidized following peptide synthesis by air oxygen 
and the cyclized peptide was seperated from linear and oligomerized material 
by reversed phase HPLC. The purified peptide was tested in ELISA with 97 
sera from HIV-1 infected persons in various stages of the disease. To exclude 
regional strain specific effects, sera from European (n = 58) and African 
(n = 39) seropositive donors were used. Almost 90% of all randomly selected 
sera of HIV-1 infected persons reacted positively with the V3-C36 independent 
of the clinical stage of the disease and the origin of the tested sera. This is in 
clear contrast o recent investigations reporting the reactivity of 86 random 
AIDS patient sera with the commonly used HIV-1/IIIB or LAV (BRU) V3 
sequences: only 14% of the tested sera showed positive reaction [15]. At least 
83% (45/54) of sera derived from asymptomatic HIV-1 patients recognized the 
V3-C36 peptide in ELISA. Differentiation between sera from European, mostly 
infected with HIV-1 types of US-origin, and African asymptomatic patients 
revealed that the positive r action with V3-C36 of African sera (13/18; 73,2%) 
is only slightly reduced if compared to the reactivity of the European sera (30/ 
36; 83%). Part of the sera from early infection status, which did not recognize 
the consensus peptide were also negative for gp 120 detection in Western blot 
analysis. Sera taken two months later from the same patients were positive to 
V3-C36. All sera from LAV-, ARC- and AIDS (symptomatic) patients tested 
showed positive reaction in ELISA, independent from their origin of Europe 
and Africa. The serological data are summarized in Fig. 2. 
Reactivity of V3-C36 with HIV-1 virus typespecific sera 
To analyse the isolate- or group-specificity of V3-C36 we tested the reactivity 
of HIV-1 typespecific sera [24] with the peptide. These sera were raised in goats 
with peptides representing the central region of the V3 domain (aa 301-321) 
of strains IIIB, MN, and RF coupled to tetanus toxoid: V3-IIIB, V3-RF and 
V3-MN specific peptide antisera recognized V3-C36 in ELISA. The reactivity 
of the 1 x 10 - z diluted sera is shown in Table 1, indicating that the peptide is 
recognized by all HIV-1 type specific sera tested so far. End point titers were 
determined using serial dilutions of V3-specific antisera. V3-C36 was recognized 
best by the V3-IIIB specific antiserum with titers of 2.4 x 10 4, the corresponding 
antisera to V3-MN and V3-RF showed titers of 3.2 x l0 3 and 1.6 x 103, re- 
spectively. Another anti V3-peptide serum, raised in rabbits against a short V3- 
consensus peptide developed in our laboratory (V3-Sla; SIHIGPGRAFVT; 
[21]) reacted with titers of 3.2 x 103 (Table 1). Moreover, abundant reaction 
with V3-C36 could be shown in ELISA using a murine monoclonal antibody 
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Fig. 2. Reactivity of AIDS patient sera in ELISA using the cyclized and purified V3-C36 
peptide as antigen. 1/100 serum dilutions of asymptomatic and symptomatic European and 
African donors were tested 
directed to the c ntral V3-IIIB sequence. A 4.8 × 10 -4 dilution of the mono- 
clonal antibody was sufficient o specifically recognize the V3-C36 peptide. 
Reactivity of antipeptide-specific antibodies dir cted to the V3-C36 peptide 
Using the V3-C36 peptide as immunogen we were able to induce polyclonal V3- 
specific antibodies in rabbits (Table 1). Resulting anti-V3 sera recognized the 
peptide with titers ranging from 1 x 10 4 to 5 X 104, depending on the V3-C36 
formulation. When appfied as a free peptide, maximum titers of 10 4 were reached 
in rabbits (serum A), when V3-C36 was conjugated to ovalbumin with carbo- 
diimide before inoculation maximum titers of 5 x 104 (serum B) were obtained 
(Table 1). Serum B was further used to test the cross reactivity of V3,-C36 specific 
antibodies in Western blot analysis using chimeric gag/V3IIIB and gag/V3- 
consensus hybrid proteins, produced by recombinant vaccinia viruses as target 
antigens [-31]. Serum B recognized both chimeric proteins with the same sen- 
sitivity independently from theV3-strain specificity. Serum dilution of l × 10 -6 
easily detected the V3 epitope of the tested fusion proteins in immunoblots. 
Further, we tested the specificity of V3-C36 specific serum B using shortened 
derivates of the V3-C36 peptides as targets in ELISA experiments (Table 2). A 
16-mer (V3-C16) and a 12-mer (V3-C12) peptide representing he central region 
of the V3-C36 peptide were sufficient o be recognized by serum dilutions of 
3.2 × 10 -3. Further shortening of the peptide to 10 (V3-C10) or 8 amino acids 
(V3-C8) drastically reduced the recognition by serum B. To confirm the cross 
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Table 1. Reactivity of type-specific antisera, a murine 
monoclonal ntibody and of two V3-C36 specific anti- 
sera in a peptide ELISA 
Antiserum to Titer 
V3-IIIB ~ 2.4 x I04 
V3-MN a 3.2 x 103 
V3-RF a 1.6 x 103 
V3-Sn b 3.2 X 10 3 
mab-V3IIIb c 4.8 x 104 
V3-C36 (serum A) d 1.0 x 104 
OVA-V3-C36 (serum B) a 4.8 x 104 
a End point titers of V3-type-specific antisera [24] 
b End point titer of an antiserum against a 12-mer 
consensus peptide [21] 
° End point titer of a murine V3-IIIB monoclonal 
antibody (Du Pont Nea 9301) 
a End point titers of antisera raised in rabbits 
against he V3-C36 peptide 
reactivity of serum B with V3-IIIB derived peptides in ELISA, three different 
peptides shortened asymmetrically from the COOH-terminus were used 
(Table2). A 16-mer V3-IIIB peptide (V3-IIIB16) was recognized from serum 
dilutions up to 3.2 x 10 -3, thus showing a comparable reactivity with serum 
B as the corresponding V3-C16 peptide. V3-IIIB derived shortened peptides (V3- 
IIIB11; V3-IIIB10) required significantly lower serum dilutions for specific rec- 
ognition (4 x 10-2; 1 x 10-2). A similar reactivity was already mentioned for 
the V3-C36 subfragments. A single amino acid exchange (P to L) in the ~-turn 
motif of the V3-C36 peptide reduced the reaction of the peptide with serum B 
almost by a factor of 10. Further analysis used peptides that represent the V3- 
corresponding region (t6aa) of unrelated HIV-1 isolates (V3-MN16, -RF16, - 
SF216, and -WMJ216), also including African virus strains (V3-Z616, -Iy116, and 
-Mall6) as antigens. The interpretation of the ELISA experiments revealed a
broad cross reactivity of serum B also with peptides derived from unrelated 
HIV-1 V3-sequences. However, the quantity of cross reaction is dependent on 
the individual isolate and is slightly reduced as compared to the recognition of 
the original 16-mer V3-C16 consensus peptide (Table 2). In competition ELISA 
experiments, none of the shortened peptides, depicted in Table 2 was capable 
to block or even significantly reduce the reactivity of patient sera or serum B 
to V3-C36. Using the complete peptide in the competition experiment, reactivity 
was reduced almost o background level (data not shown). 
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Table 2. Crossreactive properties of an antiserum raised in rabbits against the 36-mer 
V3-consensus peptide in ELISA experiments 
Peptide a aa-Sequence Titer serum B 
V3-C16 RIRIGPGRAFVTIGKI 3.2 x 103 
V3-CI2 RIGPGRAFVTIG 3.2 x 103 
V3-C10 RIGPGRAFVT 1.0 x 102 
V3-C 8 GPGRAFVT 1.0 x l02 
V3-L16  RIRIGLGRAFVTIGKI 4.0 x l02 
V3- I I IB16  RIQRGPGRAFVTIGKI 3.2 x 10 3 
V3- I I IB11  RIQRGPGRAFV 4.0 x 10 2 
V3- I I IB10  RIQRGPGRAF 1.0 x 10 2 
V3-MN~6 RIHIGPGRAFYTTKNI 1.6 x 10 3 
V3-RF16 SITKGPGRVIYATGQI 8.0 x 102 
V3-SF216 SIYIGPGRAFHTTGRI 8.0 x 102 
V3-WMJ216 SLSIGPGRAFRTREII 4.0 x 102 
V3-Z616 STPIGLGQALYTTRGR 8.0 x 102 
V3-IYt16 STPIGLGQALYTTRIK 4.0 x 102 
V3-MAL16 GIHFGPQALYTTGIV 2.0 x 102 
Equimolar atios of the peptides indicated were used for immobilization on ELISA 
plates; the numbers following the designation f the HIV-strain correspond to the length 
of the tested peptides; C and L correspond to the used type of the tested consensus peptide 
Table 3. HIV neutralization assay. Neutralizing activity of the V3-C36 derived antiserum 
(serum B) 
Serum Serum RT activity Syncytia 
dilution (cpm) × 10 3 formation 
Mock - 2.0 - 
B+ 1 :4  3 .2  - 
B -  1 : 4 48.2 + 
B+ Preimmune serum; B -  immune serum 
Reactivity of V3-C36 peptide specific antibodies in HIV-IIIB specific 
neutralization tests 
To prove the functionality of  V3-C36 induced antibodies in vitro, we performed 
a virus neutralization test (NT) using Jurkat cells as targets for infection with 
HIV-I I IB. This virus strain was selected with respect o the good recognition 
of  V3-IIIB derived peptides in the EL ISA experiments reported. As shown in 
Table 3, 1:4 dilutions of the antipeptide serum B inhibited virus replication 
and syncytia formation. As shown by RT assays done with the supernatant of  
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the infected cells and by microscopic ontrol of the cell culture, neither RT 
activity in the cell culture supernatant, nor formation of syncytia could be 
detected up to 14 days p.i., indicating a complete neutralization of HIV-IIIB 
virus by antibodies of the V3-C36 peptide. These results indicate that neutralizing 
antibodies can be induced by synthetic peptides which are not identical with 
any of the reported V3 sequences. Thus we suggest that induction of a group-, 
not only type-specific humoral immune response on the basis of synthetic 
antigens hould be possible. 
Recognition of V3-C36 peptides by cellular immunity 
A murine H2-D d restricted CTL-cell epitope is located in the V3 loop sequence 
of HIV-IIIB and has been characterized in its immunological properties (27- 
29). To confirm the functional conservation f this epitope in our V3-C36 peptide, 
recognition to V3-C36 derived peptides was tested in a 3 h cytolytic assay. Spleen 
cells were isolated from BALB/c mice two months after immunization with an 
gp 120-IIIB recombinant vaccinia virus VSC25. After a 7 days in vitro resti- 
mulation with the gp 120-IIIB recombinant vaccinia virus, spleen cells were used 
as effector cells. The p818 mastozytoma target cells were incubated with different 
concentrations of the indicated peptides (Fig. 3; 10~tm, 0.1 gm, 0.001 lxm). In- 
cubation of the target cells with the consensus 16-mer peptide (V3-16) resulted 
in specific lysis comparable to that of the HIV-IIIB/BH10 specific peptide 
present in the gp 120 protein sequence of VSC25 used for priming (Fig. 3, BH10 
(VSC25) and V3-16). Shortening of the consensus peptides by two residues 
from the NH2- and COOH-terminal end of the peptide (V3-12) decreased in 
In vivo priming: VSC 25 (BH10) 
In vitro restimulation: VSC 25 (BHU] 
BH10 (VSC 25) [ V3-16 
i z ~1~!8~)"  RIQRGPGRAFVTIGK[RIRIGPGRAFVTIGK1 
10l 
0 
50 1 50 
V3-12 V3-10 
i 
PGRAFVTIG RI PGRAFVT 
5O I 5O 
E:T ratio 
Fig. 3, Cross reactivity of H2-D d restricted murine CTLs after vaccinia-env-IIIB mediated 
in vivo priming and in vitro restimulation with a IIIB/BH10-derived 16-mer V3 peptide 
BHIO (FSC25) and different truncated erivatives of the V3-C36-consensus peptide (V3- 
16; V3-12; V3-10). p815 target cells were preincubated with different concentrations of the 
indicated peptides [10gM (O), 0.1 gM (O) and 1 nM (x)].  % specific lysis achieved by 
the use of different E/T ratios (1-50) are indicated 
Immunological reactivity of a HIV-1 derived peptide t49 
H2-D a restricted recognition by the effector cells (Fig. 3). Further shortening 
by 2 amino acids from the carboxy terminus (Fig. 3, V3-10) completely abolished 
the killing effect. Reduction of the peptide concentration also decreases the H2- 
D d restricted recognition of the peptide-treated targets by the effector cells. 
Discussion 
The envelope proteins of HIV-1 show a high extent of overall variability in the 
amino acid sequences of the individual isolates. Variability, however, is con- 
centrated in defined regions, which show all parameters for a high probability 
of surface exposition of the protein in combination with consensus-sites for 
carbohydrate modification. Variable domains are stabilized by flanking con- 
served cysteine residues to form highly exposed loop structures representing 
antigenic domains. Although the variable region 3 contains no consensus sites 
for N-glycosylation, but a fairly conserved central sequence motif (GPGR), the 
immunological recognition of this epitope is, however, highly isolate specific 
and thus may allow the virus to evade the humoral immune response by con- 
tinuously forming mutant virus type in individual patients. 
Isolate specificity of antibodies to the V3-region of gp 120 was overcome by 
designing a consensus sequence, which was tested in its properties in form of 
a cyclized synthetic oligopeptide. In ELISA-tests using sera from HIV-1 positive 
individuals from Europe and Africa, the overall reactivity of the compound 
could be shown to be 90%. A negative reaction was only observed in the group 
of asymptomatic patients. Those sera were also not reactive with gp 120 on 
Western blots, but showed conversion to positive reaction in a serially taken 
serum sample. Therefore, it may be concluded that non-reactivity of these sera 
is due to a very early phase of HIV infection, where envelope specific immun- 
globulines are not found. All sera with a gp 120 positive reaction on Western 
blots irrespective of their origin in Europe and Africa tested so far showed 
positive reaction with the V3-C36 peptide. The reactivity of the peptide is thus 
not isolate- but group specific. Due to its broad serological reactivity, the V3- 
C36 peptide might have special value for diagnostic purposes. Since vertical 
transmission of the virus during pregnancy can be correlated to the absence of 
maternal V3-specific antibodies [6], determination f V3-antibody titers might 
be a further criterion for the decision whether to continue pregnancy or not. 
The high degree of cross reactivity was confirmed by the recognition of the V3- 
C36 peptide with a strain specific monoclonal ntibody (V3-IIIB) and polyclonal 
antisera directed to the V3-regions of HIV-IIIB, RF and MN. Sera obtained 
after inoculation of the V3-consensus peptide in rabbits recognized peptides 
spanning the core-sequences of the V3-domain of various HIV-isolates equally 
well, indicating that antibodies directed to the V3-consensus sequence are not 
virus isolate specific. 
The HIV-IIIB neutralizing capacity of the V3-C36 anti-peptide s rum could 
be shown in vitro, thus underlining the functional significance of the antibodies 
raised in rabbits against he V3-C36 peptide. In addition, mouse cytotoxic T- 
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cells specific for HIV-IIIB recognized target cells presenting the V3-consensus 
peptides in context o H2-D d. Those reactivities how that the functional properties 
of the V3-region to induce humoral and cellular immune response were not 
destroyed by the construction of the consensus equence. It can be concluded that 
by comparison of amino acid sequences and functional parameters of the V3- 
loop, a domain with a new, naturally not existing sequence can be proposed, which 
exhibits additional new properties. The functional importance of the V3-region to 
induce HIV-neutralizing immune reaction as welt as V3 specific CTLs in 
the course of virus infection makes the V3 consensus equence with its group-, 
not isolate-specific properties a candidate-epitope to be included in a potential 
vaccine inducing cross protection to a variety of HIV-isolates. 
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